Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …

Abstract▴ The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine
(dTpa) is intended for use as a booster dose in individuals aged≥ 4 years.▴ A single dose …

BACKGROUND: Older adults, especially those over 65 years, are at risk of more severe
morbidity from diphtheria, tetanus and pertussis and may transmit pertussis to unvaccinated …

At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …

Background Over the last decades, pertussis showed periodic increases in its incidence
among adults, despite being a vaccine-preventable disease. Methods This phase III …

Background: The rising incidence of pertussis amongst adults and adolescents in
industrialised countries could be reduced by replacing tetanus and diphtheria (Td) boosters …

Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

Background Reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap)
vaccine is recommended in many countries for boosting immunity in adolescents and adults …

Background In a prospective, randomized pivotal phase III clinical trial, the immunogenicity
and reactogenicity of a tetanus-diphtheria-acellular pertussis vaccine (Tdap) and a tetanus …